Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States
Clinical Therapeutics- United States
doi 10.1016/j.clinthera.2017.08.010
Full Text
Abstract
Available in
Categories
Date
October 1, 2017
Authors
Publisher
Elsevier BV